scholarly journals Physical Activity for Symptom Management in Women With Metastatic Breast Cancer: A Randomized Feasibility Trial on Physical Activity and Breast Metastases

2019 ◽  
Vol 58 (6) ◽  
pp. 929-939 ◽  
Author(s):  
Jasmine Yee ◽  
Glen M. Davis ◽  
Daniel Hackett ◽  
Jane M. Beith ◽  
Nicholas Wilcken ◽  
...  
2018 ◽  
Author(s):  
Lidia Delrieu ◽  
Olivia Pérol ◽  
Béatrice Fervers ◽  
Christine Friedenreich ◽  
Jeff Vallance ◽  
...  

BACKGROUND About 5% of breast cancer cases are metastatic at diagnosis, and 20%-30% of localized breast cancer cases become secondarily metastatic. Patients frequently report many detrimental symptoms related to metastasis and treatments. The physical, biological, psychological, and clinical benefits of physical activity during treatment in patients with localized breast cancer have been demonstrated; however, limited literature exists regarding physical activity and physical activity behavior change in patients with metastatic breast cancer. OBJECTIVE The primary objective of this study is to assess the feasibility of a 6-month physical activity intervention with activity trackers in patients with metastatic breast cancer (the Advanced stage Breast cancer and Lifestyle Exercise, ABLE Trial). Secondary objectives are to examine the effects of physical activity on physical, psychological, anthropometrics, clinical, and biological parameters. METHODS We plan to conduct a single-center, single-arm trial with 60 patients who are newly diagnosed with metastatic breast cancer. Patients will receive an unsupervised and personalized 6-month physical activity program that includes an activity tracker Nokia Go and is based on the physical activity recommendation. Patients will be encouraged to accumulate at least 150 minutes per week of moderate-to-vigorous intensity physical activity. Baseline and 6-month assessments will include anthropometric measures, functional tests (eg, 6-minute walk test and upper and lower limb strength), blood draws, patient-reported surveys (eg, quality of life and fatigue), and clinical markers of tumor progression (eg, Response Evaluation Criteria In Solid Tumors criteria). RESULTS Data collection occurred between October 2016 and January 2018, and the results are expected in August 2018. CONCLUSIONS The ABLE Trial will be the first study to assess the feasibility and effectiveness of an unsupervised and personalized physical activity intervention performed under real-life conditions with activity trackers in patients with metastatic breast cancer. CLINICALTRIAL ClinicalTrials.gov NCT03148886; https://clinicaltrials.gov/ct2/show/NCT03148886 (Accessed by WebCite at http://www.webcitation.org/71yabi0la) REGISTERED REPORT IDENTIFIER RR1-10.2196/10487


Author(s):  
Lidia Delrieu ◽  
Agnès Martin ◽  
Marina Touillaud ◽  
Olivia Pérol ◽  
Magali Morelle ◽  
...  

Abstract Purpose Sarcopenia has been identified as an important prognostic factor for patients with cancer. This study aimed at exploring the potential associations between a 6-month physical activity intervention and muscle characteristics, sarcopenia, oxidative stress and toxicities in patients with metastatic breast cancer. Methods Women newly diagnosed with metastatic breast cancer (N = 49) participated in an unsupervised, personalized, 6-month physical activity intervention with activity tracker. Computerized tomography images at the third lumbar vertebra were analysed at baseline, three months and six months to assess sarcopenia (muscle mass index < 40 cm2/m2) and muscle quality (poor if muscle attenuation < 37.8 Hounsfield Units). Oxidative markers included plasma antioxidant enzymes (catalase, glutathione peroxidase and superoxide dismutase activities), prooxidant enzymes (NADPH oxidase and myeloperoxidase activities) and oxidative stress damage markers (advanced oxidation protein products, malondialdehyde (MDA) and DNA oxidation. Results At baseline 53% (mean age 55 years (SD 10.41)) were sarcopenic and 75% had poor muscle quality. Muscle cross sectional area, skeletal muscle radiodensity, lean body mass remained constant over the six months (p = 0.75, p = 0.07 and p = 0.75 respectively), but differed significantly between sarcopenic and non-sarcopenic patients at baseline and 6-months. Sarcopenic patients at baseline were more likely to have an increase of MDA (p = 0.02) at 6 months. Being sarcopenic during at least one moment during the 6-month study was associated with a higher risk of developing severe toxicities (grade > 2) (p = 0.02). Conclusions This study suggests potential benefits of physical activity for maintenance of muscle mass. Sarcopenia can alter many parameters and disturb the pro and antioxidant balance.


2013 ◽  
Author(s):  
Arianna Aldridge-Gerry ◽  
Oxana G. Palesh ◽  
Firdaus S. Dhabhar ◽  
Jamie M. Zeitzer ◽  
Booil Jo ◽  
...  

2010 ◽  
Author(s):  
Susan Sharp ◽  
Ashleigh Golden ◽  
Cheryl Koopman ◽  
Eric Neri ◽  
David Spiegel

2021 ◽  
Author(s):  
Jennifer A Ligibel ◽  
Luke Huebner ◽  
Hope S Rugo ◽  
Harold J Burstein ◽  
Debra L Toppmeyer ◽  
...  

Abstract Background Obesity and inactivity are associated with increased risk of cancer related- and overall mortality in breast cancer, but there are few data in metastatic disease. Methods CALGB 40502 was a randomized trial of first-line taxane-based chemotherapy for patients with metastatic breast cancer. Height and weight were collected at enrollment. After 299 patients enrolled, the study was amended to assess recreational physical activity (PA) at enrollment using the Nurses’ Health Study Exercise Questionnaire. Associations with progression-free survival (PFS) and overall survival (OS) were evaluated using stratified Cox modeling (strata included hormone receptor status, prior taxane, bevacizumab use, and treatment arm). Results 799 patients were enrolled and at the time of data lock, median follow-up was 60 months. At enrollment, median age was 56.7 years, 73.1% of participants had hormone receptor-positive cancers, 42.6% had obesity, and 47.6% engaged in less than 3 metabolic equivalents of task (MET)-hours of PA/week (&lt;1 hour of moderate PA). Neither baseline body mass index nor PA was statistically significantly associated with PFS or OS, although there was a marginally statistically significant increase in PFS (hazard ratio = 0.83, 95% confidence interval [CI] = 0.79, 1.02; p = .08) and OS (hazard ratio = 0.81, 95% CI = 0.65, 1.02; p = .07) in patients who reported PA greater than 9 MET-hours/week vs 0–9 MET-hours/week. Conclusions In a trial of first-line chemotherapy for metastatic breast cancer, rates of obesity and inactivity were high. There was no statistically significant relationship between body mass index and outcomes. More information is needed regarding the relationship between PA and outcomes.


2018 ◽  
Vol 29 ◽  
pp. viii116
Author(s):  
B. Fervers ◽  
L. Delrieu ◽  
O. Pérol ◽  
O. Febvey-Combes ◽  
A. Dufresne ◽  
...  

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 6640-6640 ◽  
Author(s):  
Yvonne Y. Lei ◽  
Katharine M. Quain ◽  
Don S. Dizon ◽  
Rachel Jimenez ◽  
Jennifer Adrienne Shin ◽  
...  

6640 Background: Costs of cancer care may impact access to therapy, adherence, and distress among patients. However, the degree to which patients with metastatic breast cancer (MBC) wish to discuss financial issues when making treatment decisions is unknown. Methods: In a single arm feasibility trial, 40 women with newly diagnosed or progressive MBC completed a 1-page survey regarding goals and priorities for discussion with the oncology team. The survey included 17 potential priorities for discussion in the domains: treatment options, symptom management, emotional concerns, planning for the future, and lifestyle. We evaluated participants’ interest in prioritizing discussion of financial issues and sociodemographic and clinical correlates of this preference. We examined the relationship between desire to discuss financial issues and both distress on the Distress Thermometer (DT) and satisfaction with cancer care using Fisher’s exact test. Results: Among 40 participants, 11 (28%) reported interest in discussing financial issues when making treatment decisions, 29 (72%) were not interested. Average age was 57 (range 31-73), and the majority were white (85%) and college graduates (66%). Only 18% of white patients were interested in addressing cost, while 83% of non-white patients were interested (p < 0.01). Those with a college education were less likely to prioritize financial discussion compared to no college (16% vs. 47%, p = 0.04). Patients interested in discussing cost were more likely to have a household income < $50,000 (50% vs. 22% > $50,000, n.s.) and to have Medicaid (50% vs. 25% other insurance, n.s.). Additionally, patients with higher levels of distress (35% vs. 21% DT < 4, n.s.) and those on novel targeted or biologic therapy (42% vs. 21% other therapy, n.s.) were more likely to prioritize discussion of costs. Desire to discuss cost was not related to satisfaction with care. Conclusions: A substantial minority of patients with MBC, particularly those from less advantaged backgrounds, wish to discuss financial issues at time of treatment decisions. Financial toxicity research should recognize that not all patients desire this discussion and evaluate methods to screen for financial concerns and barriers to care.


2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 11622-11622
Author(s):  
Jeffrey M. Peppercorn ◽  
Yvonne Y. Lei ◽  
Nora Horick ◽  
Katharine M. Quain ◽  
Don S. Dizon ◽  
...  

11622 Background: Individualized treatment planning is a critical part of quality cancer care, but how best to achieve this for patients with metastatic breast cancer (MBC) is unclear. We evaluated the feasibility, acceptability and impact of using a simple and scalable “Individualized Goals of Care Discussion Guide” (IGCDG) to facilitate patient-provider communication at the time of treatment decisions. Methods: We developed the IGCDG based on structured interviews with MBC patients and input from experts in cancer care, decision sciences, psychology and palliative care. We then conducted a single arm feasibility trial among patients with newly diagnosed or progressive MBC. Prior to clinic, patients received the IGCDG, an 8-page MBC informational brochure and 1-page questionnaire regarding treatment preferences, personal goals and priorities for care planning. The completed questionnaire was provided to the oncology team at the patient’s visit. Pre and post assessment included the Distress Thermometer (DT), Patient Satisfaction with Cancer Care Scale and the Control Preferences Scale. Feasibility was defined as: 1) accrual of > 50%, 2) attrition rate < 32%, and 3) < 50% of patients experiencing increased distress following the intervention. Results: Among 60 eligible patients, 42 participated (70% accrual), 40 completed all surveys (2% attrition), and only 7 (18%) reported increased distress. Mean age was 57 (range 31 – 79), 85% were white, 7% black, 5% Hispanic, 66% were college graduates, and 40% reported high baseline distress (DT > 4). Patient priorities for discussion included cancer directed therapy (70%), symptom management (70%), and prognosis/planning ahead (60%). At 2-month follow-up, 53% reported decreased distress compared to baseline. Satisfaction with cancer care was high at baseline and follow-up. Most patients preferred shared decision making (77%), and 79% reported decision roles concordant with preferences. Overall, 72% of participants found the IGCDG helpful, 93% found the questionnaire easy to complete, and 44% felt it improved communication with their doctor (49% unsure). Conclusions: Administration of the Individualized Goals of Care Discussion Guide is feasible and provides patients with MBC an opportunity to define their goals of care and priorities for discussion in clinic. Clinical trial information: NCT03375827.


Sign in / Sign up

Export Citation Format

Share Document